NOVARTIS: OVARIAN CANCER DRUG DISAPPOINTS IN TRIAL (AP)
Thursday, May 27th, 2010AP – land take concern Novartis AG said weekday it won’t communicate regulators for authorisation to mart a newborn ovarian cancer take after a late-stage effort evidenced disappointing.

Vota
